Botanicals, which have been part of human food and medicine for thousands of years, are perceived as being safer than synthetic pharmaceuticals. The global botanical drug market was expected to reach $26.6 billion by 2017. In terms of FDA regulations, botanical drugs are no different from non-botanical products, having to meet the safety and effectiveness standards of a new drug in accordance. This book comprises a complete start-to-end process from drug-idea conception, to drug development process.

Key Features:

• Provides a complete compendium for botanical drug products
• Describes what BDP is and how it differs from Pharma, Biopharma, and Nutraceuticals
• Compiles all critical regulatory steps in a variety of countries
• Discusses clinical trial management for BDP development and how it differs from conventional chemical-based drugs and biopharmaceutics